Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Chemical modification or the reaction product thereof – e.g.,...
Reexamination Certificate
2008-09-02
2008-09-02
Le, Long V. (Department: 1641)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Chemical modification or the reaction product thereof, e.g.,...
C530S402000, C530S405000, C530S406000, C436S544000, C544S105000
Reexamination Certificate
active
10732767
ABSTRACT:
The invention provides derivatives of efavirenz and methods of making derivatives of efavirenz. The derivatives include immunogenic compounds for producing antibodies to efavirenz and labeled efavirenz tracers. These compounds are useful in immunoassay methods for determining efavirenz.
REFERENCES:
patent: 5633405 (1997-05-01), Thompson et al.
patent: 5874430 (1999-02-01), Christ et al.
patent: 2004/0214251 (2004-10-01), Sigler et al.
patent: 1470825 (2004-10-01), None
patent: WO03/006506 (2003-01-01), None
Rizzo et al. Prediction of activity for nonnucleoside inhibitors with HIV-1 Reverse transcriptase based on monte carlo simulations. J. Med. Chem. 2002, vol. 45, pp. 2970-2987.
Patel et al. Synthesis and evaluation of analogs of efavinz (Sustiva) as HIV-1 reverse transcriptase inhibitors. Bioorg. Med. Chem. Lett. 1999, pp. 2805-2810.
Mutlib et al. “Identification and Characterization of Efavirenz Metabolites by Liquid Chromatography/Mass Spectrometry and High Field NMR: Species Differences in the Metabolism of Efavirenz”. Drug Metabolism and Disposition, vol. 27, No. 11, pp. 1319-1333, 1999.
Marzolini et al., “Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patents”. AIDS 2001, 15: 71-75.
Singh et al., “Cesium Fluoride Catalyzed Trifluoromethylation of Esters, Aldehydes, and Ketones with (Trifluoromethyl) Trimethylsilane”, J. Org Chem 1999, 64, 2873-2876.
Radesca, et al., “Synthesis of HIV-1 Reverse Transcriptase Inhibitor DMP 266”, Synthetic Communications, 27(24), 4373-4384 (1997).
Zhuyin Li et al., “New Synthesis and Characterization of (+) Lysergic Acid Diethylamide (LSD) Derivatives and the Development of a Microparticle-Based Immunoassay for the Detection of LDS and Its Metabolites”, Bioconjugate Chem. 1997, 8, 896-905.
Prakash, G.K., Yudin AK, “Perfluoroalkylation with Organosilicon Reagents”, Chem Rev 1997, 97, 757-786.
Patel, et al., “Synthesis and Evaluation of Analogs of Efavirenz (Sustiva™) as HIV-1 Reverse Transcriptase Inhibitors”, Bioorganic & Medicinal Chemistry Letters 9 (1999), 2805-2810.
Akeb, F. et al., “Quantification of plasma and intracellular levels of the HIV protease inhibitor ritonavir by competitive ELISA,” Journal of Immunological Methods 263 (2002) 1-9.
Rezk, N. et al., “Simple and rapid quantification of the non-nucleoside reverse transcriptase inhibitors nevirapine, delavirdine, and efavirenz in human blood plasma using high-performance liquid chromatography with ultraviolet absorbance detection,” Journal of Chromatography B, 774 (2002) 79-88.
Ghoshal Mitali
Ouyang Anlong
Sigler Gerald
Amick Marilyn L.
Haq Shafiqul
Le Long V.
Roche Diagnostics Operations Inc.
Roche Diagnostics Operations Inc.
LandOfFree
Reagents for detecting efavirenz does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Reagents for detecting efavirenz, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Reagents for detecting efavirenz will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3935495